Tissue-specific expression
Our initial approach was to develop tissue specificity of transgene expression, by using tissue or tumor-restricted promoters to regulate a TET-derived transcription factor (tTA) which drives transcription of the selected transgene (FasL, Apoptin, Bax or TRAIL) [1] [2] [3] [4] [5] [6] [7] [8] [9] (See Figure 1a) . We successfully carried out such studies with adenoviral vectors and demonstrated restricted gene expression. 1 To target expression to the prostate, we utilized a modified rat probasin promoter AAR2PB developed by the Matusik laboratory. 10, 11 We have shown tissue selectivity of the prostate targeting vector, and we demonstrated that it can be injected into the mouse tail vein at 1 Â 10 9 pfu with no negative effect on mouse survival and no observable liver damage. 1 Conversely, if we inject a virus with a CMV driven GFPFasL fusion gene, the mice die within 24 h. These data demonstrate restricted expression is occurring. Of special note, this virus is designed for orthotopic use in human gene therapy and any reasonably sized promoter can be inserted in the regulatory region to target tumors or specific tissues.
Most recently, we have shifted our focus to head and neck cancer (HNSCC) xenografts and we are now developing a vector that specifically targets tumor versus normal tissue using a tumor-specific promoter. Based on our data with this model and because of its general accessibility for orthotopic injection, this will likely be our first target for a Phase I clinical trial.
Transgene amplification
A second approach we employed was to design a virus that would amplify therapeutic transgene expression. To accomplish this, we utilized a modification of the TET (tTA) regulatory system originally developed by Herman Bujard. 12 In order to provide for tighter tissue-specific regulation of transgene expression, we separated the transcriptional activator gene from the transgene by cloning in the left and right arms of a complex Ad5 virus to create the vector depicted in Figure 1a and b. The methods for this approach are published. 9, 13 The two gene therapy vectors we are most experienced with are a GFP fusion to the N-terminus of the mouse FasL gene 14 and a GFP fusion to the N-terminus of the VP3 gene (Apoptin) of the chicken anemia virus. 15, 16 The basic advantage of our complex adenovirus delivery system is transcriptional regulation of the transgene (through the TET-Off system). Gene expression from this virus is about five times more potent than expression of a reporter gene using only the tissue-specific promoter alone as described in Rubinchik et al. 1 As discussed above, tissue specificity of this virus has also been demonstrated in vivo 1 and was based on the ARR2PB 10, 11 promoter placed in position A as depicted in Figure 1 . A second feature is that transgene expression is downregulated by doxycycline. We reasoned that when using FasL the potential for adverse events exists if the virus leaks from the orthotopic administration site and enters the systemic circulation. This can be monitored by using a liver function assay. Should we observe an unusual spike in the liver enzyme profile (ALT, AST) we can immediately and continuously administer doxycycline to turn off transgene expression and ameliorate the adverse event.
Eliciting bystander activity
Our third approach, which we are optimistic about vis-a`-vis human application, is to develop ways to amplify the therapeutic function of the transgene through a bystander effect. The bystander effect is defined as when cells in a tumor are infected by the viral vector, undergo cell death, and subsequently transmit additional death signals to adjacent uninfected cells. We have previously demonstrated 17 that bystander activity is elicited by AdGFPFasL administration and the effect is mediated by FasL expressed on apoptotic vesicles. This approach clearly shows promise and its proposed mechanism is presented in Figure 2a which depicts two cancer cells and the possible sites where FasL, presented by apoptotic vesicles, can initiate an autocrine or paracrine FasLmediated killing event. We also envision the possibility of direct cell-cell contact involving FasL-Fas as a possible route to signal apoptosis. We initiated these studies because in our prostate cancer xenograft experiments, 2 we noticed that about half of the AdGFPFasL TET -treated tumors were substantially reduced or eradicated. Earlier we had carried out studies on delivery of a control virus expressing LACZ (unpublished) and realized we were unable to infect more than 15-20% of the cells in the tumor bed under the best of conditions. Our in vivo results with AdGFPFasL led us to the hypothesis that the virus was inducing a bystander effect and/or recruiting immune cells to the tumor and we initiated studies to learn if this was correct. 2 To address this, we prepared apoptotic vesicles from cells killed in tissue culture by AdGFPFasL. 17 Partially purified apoptotic vesicles were used to perform dose-response curves that measured programmed cell death events in a panel of prostate cancer cells. It was a pleasant surprise to see that apoptotic vesicles maintained a FasL-directed killing mechanism in most prostate cancer and control cell lines. We have subsequently demonstrated that this approach also works in a similar fashion in head and neck cancer cell lines of squamous cell origin, 18 and in human renal cancer cells. 19 
Mechanism of bystander action
There are at least three possibilities to explain bystander activity (Figure 2b ). The first is a direct FasL-mediated cell killing mechanism via apoptotic vesicles. 17 The second is that, unpublished experiments carried out with Steve Tomlinson and Charles Landon, suggest that following FasL virus administration, neutrophils and natural killer cells (NK) cells are recruited into the tumor bed as has also been reported by the Nabel laboratory. 20, 21 Even in the context of a nude mouse model, these cells have the potential for creating both an inflammatory response and a cell-directed tumor killing mechanism. The third possibility is that FasL either presented by apoptotic vesicles, or by direct viral infection of vascular endothelium, damages the blood supply to the tumor. For example, we know AdGFPFasL-induced apoptotic vesicles kill human endothelial cells (HUVEC, unpublished) in tissue culture which suggests endothelial cells lining tumor blood vasculature may also be susceptible to this. Studies to confirm this are planned using in vivo imaging technology.
Resistance to bystander activity
As a caveat, we have observed a potential problem related to the effectiveness of bystander activity in some cancer cells that appear to be resistant to FasL signaling from the external surface of the cell 8, 17 regardless of the signal source (immune cells or apoptotic vesicles). The mechanism of resistance lies in part with the observation that tumor cells frequently upregulate genes involved in inhibition of apoptosis, including FLIP s , 22 Survivin and cIAP1. 18, [22] [23] [24] [25] This led to the concept discussed below, in which FasL gene therapy is combined with agents that downregulate the anti-apoptotic phenotype of tumors creating a more pro-apoptotic phenotype which facilitates bystander activity. This has already been tested in prostate tumor xenograft using TRAIL, Apoptin and FasL [23] [24] [25] and in head and neck xenografts (unpublished).
Ceramide metabolism and resistance to FasL signaling
Our fourth approach for amplifying FasL gene therapy has been examination of ways to modify ceramide metabolism and induce a pro-apoptotic phenotype in cancer cells in order to promote a bystander-mediated event leading to tumor eradication. In this regard, we have successfully developed and tested a series of acid ceramidase inhibitors that enhance FasL killing both in vitro and in vivo. 18, 19, 24, 25 The following provides the reasoning for this concept.
One of the key signaling molecules in cells is ceramide which has been called a 'tumor suppressor lipid'. 26 Ceramide metabolism in tumors is affected by a multitude of signaling mechanisms (reviewed in Ogretmen et al. 27 ), including stress via hypoxia, nutrient deprivation, heat, viral infection, radiation, chemotherapy and receptormediated signaling of a variety of growth factors and cytokines including TNF, FasL and TRAIL. When ceramide is elevated in the cell, it creates a pro-apoptotic phenotype by virtue of its ability to inhibit growth through cell cycle arrest and/or induction of apoptosis. Ceramide is generated in the cell by de novo synthesis, by action of sphingomyelinases or through salvage pathways. 24, 27 Ceramide can be metabolized by ceramide kinase, glucosylceramide synthase, ceramidases and sphingomyelin synthases. Ceramidases (acid, neutral and alkaline) have all been shown to deacylate ceramide generating sphingosine. 27, 28 In tumors where sphingosine kinase is elevated (sphingosine itself will elevate sphingosine kinase), phosphorylation of sphingosine occurs yielding sphingosine-1-phosphate (S1P). Sphingosine-1-phosphate is established as a ligand for several of the S1P/ Edg receptors [29] [30] [31] and induces cell proliferation, transformation, angiogenesis and cell motility particularly of endothelial cells, creating an anti-apoptotic phenotype.
As indicated earlier, ceramide exerts a number of activities within the cell to elicit its responses, including activation of various ceramide-activated protein phosphatases, including PP2a and PP1. 32 It can also activate caspases through mechanisms that are not well defined. In addition, others (reviewed in Ogretmen et al. 27 ) have shown activation of ceramide-activated protein kinases acting through the RAF-MAP kinase pathway to induce inflammatory responses. The importance of the phosphatases has been examined in great detail by Hannun et al., and they have shown that PP1 is capable of dephosphorylating the serine arginine-rich family of proteins involved in alternative splicing. [32] [33] [34] [35] This leads to alternative splicing of two important apoptotic regulatory proteins, Caspase 9b to Caspase 9 and Bcl xL to Bcl xs. Both of the latter products favor induction of apoptosis within the cell.
Why is this relevant? In 2000, a paper by Seelan et al. 36 was published demonstrating that acid ceramidase (an enzyme that occurs in the lysosome and plasma membrane), is upregulated at the mRNA level in 42% percent of prostate cancer tumors. As the Gleason grade increases this percentage also increases, suggesting acid ceramidase expression is linked to tumor severity. We have begun a study of this in our laboratory by examining matched pairs of normal versus cancer tumor tissue (prostate and head and neck). We now know by Western blotting that 67% of our prostate tumor samples have upregulated expression of acid ceramidase while 70% of HNSCC do (Figure 3a and b) . Thus, these preliminary data substantiate the earlier observation by Seelan et al. 36 that many of these tumors have the potential for exhibiting an anti-apoptotic phenotype via deacylation of ceramide by lysosomal acid ceramidase.
Our lipid working group has synthesized a series of inhibitors of ceramidases which we are studying for their N1  N2  N3  N4 T4 N5 T5 N6 T6 N7 T7 N8 T8  T1   N9 T9  N10 T10 N11 T11 N12 T12 N13 T13 N14 T14 N15 T15   T2  T3   N1  N2  N3  N4  T4  N5  T5  T1  T2  T3   N6  N7  N8  N9  T9  N10  T10  T6  T7 chemotherapeutic potential (Bielawska et al., unpublished data). We now know that treating prostate or HNSCC cancer cells with the lysosomotropic ceramide analog, LCL204, induces a rapid destabilization of the lysosomes as early as 5 min after treatment. 37 Between 30-60 min ceramide levels are also elevated. Over a similar time frame specific degradation of key ceramide metabolizing proteins occurs by action of a lysosomal protease followed by release of lysosomal proteases into the cytosol. These events signal in concert to elevate p53 and p73 in a cell line-dependent manner, which is followed by upregulation and activation of Bak. Bak and p73 protein elevation depends on JNK/AP-1 and p38 MAPK activities, respectively. The overall effect is activation of mitochondria depolarization and executioner caspase activation, which culminates in apoptosis. The unique structure of LCL204 is essential for the lysosomotropic activities it displayed. These results are evidence that targeting both the lysosomes and ceramide signaling pathways with molecules such as LCL204 can serve as a viable treatment option for prostate and HNSCC and we have now demonstrated that LCL204 augments and sensitizes both prostate and HNSCC to FasL-Fas activation. 24 
Summary
In summary, this report reviews our data which explore four strategies to amplify the apoptotic response following adenoviral-delivered genes while induce apoptosis in a solid tumor environment. These data demonstrated that tissue-specific regulation of FasL expression is sufficient to provide in vivo protection to mice injected with the virus. The laboratory has also shown that the amplification system in the complex adenovirus is capable of producing sufficient transgene activity to induce both apoptosis and a bystander effect. The bystander effect is mediated, at least in part, by direct action of FasL on the Fas receptor. AdGFPFasL injection is also likely to result in immune cell recruitment and possible destruction of tumor vascular endothelium, the latter which exerts an anti-angiogenic effect. Finally, our data demonstrated that the often overlooked effect of ceramide metabolism in tumors is significant by application of inhibitors of ceramide metabolizing enzymes, in particular inhibitors of acid ceramidase, which sensitizes cells to both bystander activity and direct cell killing at low micromolar concentrations. This strongly suggests that modulation of ceramide activity in tumors is an important component of the ability of the body to rid itself cancers. Our laboratory is now moving to take both of these agents into clinical trials in head and neck cancer.
